Methadone for cancer pain.

Methadone for cancer pain. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Methadone for cancer pain. Abstract Text:

A B Nicholson,A B Nicholson,

BACKGROUND: Methadone is an opioid used in the management of cancer pain. A particular role in neuropathic pain has been suggested. The quest for evidence based palliative care prompted a formal appraisal of methadone in comparison with other analgesics. This is an updated version of the original Cochrane review published in Issue 1, 2004. OBJECTIVES: To determine effectiveness and safety of methadone analgesia in cancer pain patients. SEARCH STRATEGY: MEDLINE, EMBASE, CancerLit, CINAHL and Cochrane databases were searched in 2002 using a strategy developed with the Cochrane Pain, Palliative and Supportive Care Group. Repeat searches were conducted in September 2006. SELECTION CRITERIA: Randomised controlled trials (RCTs) of methadone against active or placebo comparator in patients with cancer pain were included. Outcome measures sought were reduction in pain intensity, adverse effects, attrition, patient satisfaction and quality of life. There were no language restrictions. DATA COLLECTION AND ANALYSIS: Eligible studies were selected with independent collaboration from a colleague. Full text was retrieved if any uncertainty about eligibility remained. Non-English texts were screened by Cochrane contacts. Quality assessment and data extraction were conducted using standardised data forms. Drug and placebo dose, titration, route and formulation were compared and detail of all outcome measures (if available) recorded. MAIN RESULTS: This updated review includes nine RCTs (six double blinded, two crossover) with 459 recruits and 392 completing patients. All studies involved active opioid comparators (morphine, dextromoramide, pethidine, diamorphine with cocaine mixture) with different dose and titration schedules and various pain scoring scales. One study differentiated cases by pain syndrome. Few presented complete pain data sets but complete adverse events data were recorded in every study. Efficacy and tolerability were broadly similar between methadone and morphine. No useful meta-analysis has been possible. AUTHORS' CONCLUSIONS: The updated review contains new information supporting the previous conclusions that methadone has similar analgesic efficacy to morphine. The additional study examined neuropathic and non-neuropathic pain, finding no superiority for methadone in the former group. The new study also addresses a clinically relevant concern about short term/single dose studies. Use beyond a few days may result in methadone accumulation leading to delayed onset of adverse effects. In an assessment over 28 days there was a higher rate of withdrawal due to side effects in the methadone group. This observation reinforces the advice that experienced clinicians should take responsibility for initiation and careful dose adjustment and monitoring of methadone.

Methadone for cancer pain. Publishing Authors By Initials

AB Nicholson,AB Nicholson,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Methadone for cancer pain. Journal Published:

PUBLICATION TYPE: Review

Journal: Cochrane database of systematic reviews (Online)

VOLUME:

Page Numbers: CD003971

Journal Abbreviation:

ISSN: 1469-493X

DAY: 17

MONTH: 10

YEAR: 2007

Methadone for cancer pain. Information

Number of References: 62

LANGUAGE: eng

NlmUniqueID: 100909747

Methadone for cancer pain. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Methadone for cancer pain. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Methadone for cancer pain.

AFFILIATION: James Cook University Hospital, Marton Road, Middlesbrough, UK, TS4 3BW. alex.nicholson@stees.nhs.uk

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Cochrane Database Syst Rev

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Methadone for cancer pain Related Publications

• Baring the soul: Paul Bindrim, Abraham Maslow and 'nude psychotherapy'.
• Changes in adolescents' sources of cigarettes.
• Charcot-Marie-Tooth with pyramidal signs is genetically heterogeneous: families with and without MFN2 mutations.
• Detection of urinary drug metabolite (xenometabolome) signatures in molecular epidemiology studies via statistical total correlation (NMR) spectroscopy.
• Helping parents with mental illness.
• Identification of QTLs for resistance to Fusarium head blight, DON accumulation and associated traits in the winter wheat variety Arina.
• Influenza vaccination and asthma: current studies and recommendations.
• Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts.
• Metabolism of 2-fluoro-4-iodoaniline in earthworm Eisenia veneta using (19)F-NMR spectroscopy, HPLC-MS, and HPLC-ICPMS ((127)I).
• Methadone for cancer pain.
• Microarray-based approach for genome-wide survey of nucleotide polymorphisms.
• Misidentification of Bordetella bronchiseptica as Bordetella pertussis using a newly described real-time PCR targeting the pertactin gene.
• Multiple roles of M-CSF in human osteoclastogenesis.
• One year on, the message from Nicholson is that he's listening.
• Polymorphisms of the prion gene promoter region that influence classical bovine spongiform encephalopathy susceptibility are not applicable to other transmissible spongiform encephalopathies in cattle.
• Potential role of the antioxidant N-acetylcysteine in slowing bone resorption in early post-menopausal women: a pilot study.
• Prediction and classification of drug toxicity using probabilistic modeling of temporal metabolic data: the consortium on metabonomic toxicology screening approach.
• Prolyl cis-trans isomerization as a molecular timer.
• Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer.
• Proton magnetic resonance spectroscopy of human urine: Excretion of 1-(3'-carboxypropyl)-3,7-dimethylxanthine by man after dosing with oxpentifylline.
• Shear bond strengths of glass-ionomer cements to sound and to prepared carious dentine.
• Solid phase extraction chromatography and NMR spectroscopy (SPEC-NMR) for the rapid identification of drug metabolites in urine.
• The autonomous premature unit.
• The child friendly healthcare initiative--an update.
• The effects of oestrogen receptors alpha and beta on testicular cell number and steroidogenesis in mice.
• The omega-atracotoxins: selective blockers of insect M-LVA and HVA calcium channels.
• The roles of mutation accumulation and selection in loss of sporulation in experimental populations of Bacillus subtilis.
• Thermodynamic dissection of the Ezrin FERM/CERMAD interface.
• Topographical variation in metabolic signatures of human gastrointestinal biopsies revealed by high-resolution magic-angle spinning 1H NMR spectroscopy.
• Weight gain may contribute to increased fracture risk in women treated with rosiglitazone.